Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | S100A4 | P26447 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16745380 | 1.00 | RAB9A (0.44) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL16745388 | 0.95 | RAB9A (0.41) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL16745384 | 0.95 | RAB9A (0.41) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL16745382 | 0.95 | RAB9A (0.41) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL16745413 | 0.85 | NPC1 (0.35) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL18193056 | 0.85 | NPC1 (0.35) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL18193055 | 0.85 | NPC1 (0.35) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL15551462 | 0.83 | S100A4 (0.42) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL29906291 | 0.83 | S100A4 (0.42) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL18193053 | 0.80 | MAOA (0.37) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481662-B2 | Seriniquinones, melanoma-specific anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481662-B2 | Seriniquinones, melanoma-specific anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150148314-A1 | SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-28 | — | — | US | disclosed |
| US-20150148314-A1 | SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148314-A1 | SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS | SDHA, KLK3, BRDT | RAB9A 2471/4885SMN1; SMN2 2167/4885ALDH1A1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.